Literature DB >> 9570480

Characterization of 5-HT1A receptor-mediated [35S]GTPgammaS binding in rat hippocampal membranes.

R H Alper1, D L Nelson.   

Abstract

Stimulation of [35S]GTPgammaS binding by serotonin (5-hydroxytryptamine, 5-HT) receptor ligands was characterized in rat hippocampal membranes. The optimized assay contained 30-50 microg protein, 300 microM GDP and 0.1 nM [35S]GTPgammaS, incubated at 37 degrees C for 20 min. At 10 microM, the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n-propylamino)tetralin [R(+)-8-OH-DPAT] stimulated GTPgammaS binding from 27.1 +/- 2.5 to 45.7 +/- 4.2 fmol/mg protein. Increasing the protein concentration did not affect the absolute difference between basal and maximal GTPgammaS binding nor the EC50, but decreased the percent stimulation. The non-selective agonists serotonin and 5-carboxamidotryptamine were 30-35% more efficacious, whereas the partial agonists buspirone and S(-)-8-hydroxy-2-(di-n-propylamino)tetralin stimulated GTPgammaS binding by 19 +/- 1 and 43 +/- 3%, respectively, compared to R(+)-8-OH-DPAT. Neither the 5-HT2 receptor agonist [(+/-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] (DOI) nor the 5-HT1A receptor antagonists WAY 100,635 (n-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-n-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride) and spiperone altered basal GTPgammaS binding. WAY 100,635 abolished the effect of R(+)-8-OH-DPAT, but only reduced the effect of serotonin by 88 +/- 3%. Finally, methiothepin antagonized R(+)-8-OH-DPAT-stimulated GTPgammaS binding and reduced basal GTPgammaS binding by itself. The reduction was not affected by WAY 100,635. We have characterized a method to assess functional activity at 5-HT1A receptors in rat hippocampal membranes by measuring agonist-induced [35S]GTPgammaS binding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570480     DOI: 10.1016/s0014-2999(97)01547-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.

Authors:  Kazuki Nagayasu; Yumi Yatani; Maiko Kitaichi; Yutaka Kitagawa; Hisashi Shirakawa; Takayuki Nakagawa; Shuji Kaneko
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography.

Authors:  Tina Pejchal; Melissa A Foley; Barry E Kosofsky; Christian Waeber
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Autoradiographic Evaluation of [(18)F]FECUMI-101, a High Affinity 5-HT1AR Ligand in Human Brain.

Authors:  J S Dileep Kumar; Mark D Underwood; Norman R Simpson; Suham A Kassir; Jaya Prabhakaran; Vattoly J Majo; Mihran J Bakalian; Ramin V Parsey; J John Mann; Victoria Arango
Journal:  ACS Med Chem Lett       Date:  2016-03-13       Impact factor: 4.345

4.  Vmat2 heterozygous mutant mice display a depressive-like phenotype.

Authors:  Masato Fukui; Ramona M Rodriguiz; Jiechun Zhou; Sara X Jiang; Lindsey E Phillips; Marc G Caron; William C Wetsel
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

5.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

6.  Characteristics of binding of [3H]WAY100635 to rat hippocampal membranes.

Authors:  Sven Parkel; Ago Rinken
Journal:  Neurochem Res       Date:  2006-08-26       Impact factor: 4.414

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.